Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. Academic Article uri icon

Overview

abstract

  • Malaria vaccines containing the Plasmodium falciparum Circumsporozoite protein repeat domain are undergoing human trials. There is no simple method to evaluate the effect of vaccine-induced responses on P. falciparum sporozoite infectivity. Unlike the rodent malaria Plasmodium berghei, P. falciparum sporozoites do not infect common laboratory animals and only develop in vitro in human hepatocyte cultures. We generated a recombinant P. berghei parasite bearing P. falciparum Circumsporozoite protein repeats. These hybrid sporozoites are fully infective in vivo and in vitro. Monoclonal and polyclonal Abs to P. falciparum repeats neutralize hybrid parasite infectivity, and mice immunized with a P. falciparum vaccine are protected against challenge with hybrid sporozoites.

publication date

  • December 15, 2002

Research

keywords

  • Erythrocytes
  • Malaria Vaccines
  • Malaria, Falciparum
  • Plasmodium falciparum
  • Protozoan Proteins

Identity

Scopus Document Identifier

  • 0037114136

Digital Object Identifier (DOI)

  • 10.4049/jimmunol.169.12.6681

PubMed ID

  • 12471098

Additional Document Info

volume

  • 169

issue

  • 12